Mitomics has launched Prostate Core Mitomic Test (PCMT) which uses the science of mitochondrial DNA (mtDNA) to accurately determine the absence or presence of cancerous cells using previously obtained prostate biopsy tissue.
PCMT is available through the company’s CLIA (Clinical Laboratory Improvement Amendments) lab in Aurora, Colorado.
Utilizing its cancerization field effect to identify molecular changes and enable detection of missed tumors, PCMT has demonstrated sensitivity of 84% and has also been shown to accurately rule out prostate cancer with a negative predictive value of 91%.
Urology Associates PC Clinical Research director Raoul Concepcion said the ability of PCMT to use mtDNA to potentially identify malignancy by detecting underlying molecular alterations in normal-appearing tissue is an important advance for managing patients whom the urologist feels may be at increased risk.